Sedation - Pipeline Review, H2 2019

Global Markets Direct’s, ‘Sedation - Pipeline Review, H2 2019’, provides an overview of the Sedation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sedation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sedation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sedation

- The report reviews pipeline therapeutics for Sedation by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Sedation therapeutics and enlists all their major and minor projects

- The report assesses Sedation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Sedation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sedation

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Drawbridge Pharmaceuticals Pty Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Paion AG

Drawbridge Pharmaceuticals Pty Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Paion AG

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sedation - Overview

Sedation - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sedation - Overview

Sedation - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sedation - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sedation - Companies Involved in Therapeutics Development

Drawbridge Pharmaceuticals Pty Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Paion AG

Sedation - Drug Profiles

(ketamine + midazolam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alphaxalone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EL-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HR-7056 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SERx-480 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GABA-A for Sedation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XK-568b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sedation - Dormant Projects

Sedation - Discontinued Products

Sedation - Product Development Milestones

Featured News & Press Releases

Feb 13, 2019: Melt Pharmaceuticals improves patent estate for sublingual non-opioid pain and sedation formulations

Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required

Oct 18, 2017: Remimazolam phase III Broncoscopy data to be presented at the Chest Annual Meeting 2017

Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU

Jun 28, 2017: Paion reports positive headline data in U.S. Phase III trial with Remimazolam for procedural sedation undergoing Bronchoscopy

Mar 28, 2017: Paion successfully completes patient recruitment in U.S. Phase III study with Remimazolam for procedural sedation during Bronchoscopy

Mar 27, 2017: Paion reports positive headline data in U.S. Clinical safety trial of Remimazolam in high-risk patients undergoing colonoscopy

Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting

Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting

Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China

Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy

Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy

Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance Patent For Remimazolam Besylate

Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment

Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Sedation, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under ...

List of Tables

Number of Products under Development for Sedation, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2019

Sedation - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2019

Sedation - Pipeline by Paion AG, H2 2019

Sedation - Dormant Projects, H2 2019

Sedation - Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Sedation, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by ...

List of Figures

Number of Products under Development for Sedation, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports